BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 22467238)

  • 21. New design of nucleotide excision repair (NER) inhibitors for combination cancer therapy.
    Gentile F; Tuszynski JA; Barakat KH
    J Mol Graph Model; 2016 Apr; 65():71-82. PubMed ID: 26939044
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decreased transcription-coupled nucleotide excision repair capacity is associated with increased p53- and MLH1-independent apoptosis in response to cisplatin.
    Stubbert LJ; Smith JM; McKay BC
    BMC Cancer; 2010 May; 10():207. PubMed ID: 20470425
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIF Inactivation of p53 in Ovarian Cancer Can Be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity.
    Parmakhtiar B; Burger RA; Kim JH; Fruehauf JP
    Mol Cancer Res; 2019 Aug; 17(8):1675-1686. PubMed ID: 31088908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced XPA mRNA levels in cisplatin-resistant human ovarian cancer are not associated with XPA mutations or gene amplification.
    States JC; Reed E
    Cancer Lett; 1996 Nov; 108(2):233-7. PubMed ID: 8973600
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Two-stage induced differentiation of OCT4+/Nanog+ stem-like cells in lung adenocarcinoma.
    Li R; Huang J; Ma M; Lou Y; Zhang Y; Wu L; Chang DW; Zhao P; Dong Q; Wu X; Han B
    Oncotarget; 2016 Oct; 7(42):68360-68370. PubMed ID: 27588392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulation of DNA repair gene expression in human cancer cell lines.
    McGurk CJ; Cummings M; Köberle B; Hartley JA; Oliver RT; Masters JR
    J Cell Biochem; 2006 Apr; 97(5):1121-36. PubMed ID: 16315315
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High expression of XPA confers poor prognosis for nasopharyngeal carcinoma patients treated with platinum-based chemoradiotherapy.
    Fu X; Hu J; Han HY; Hua YJ; Zhou L; Shuai WD; Du WY; Kuang CM; Chen S; Huang W; Liu RY
    Oncotarget; 2015 Sep; 6(29):28478-90. PubMed ID: 26156020
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An investigation of the molecular basis for the synergistic interaction of tirapazamine and cisplatin.
    Goldberg Z; Evans J; Birrell G; Brown JM
    Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):175-82. PubMed ID: 11163512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 14-3-3σ confers cisplatin resistance in esophageal squamous cell carcinoma cells via regulating DNA repair molecules.
    Lai KK; Chan KT; Choi MY; Wang HK; Fung EY; Lam HY; Tan W; Tung LN; Tong DK; Sun RW; Lee NP; Law S
    Tumour Biol; 2016 Feb; 37(2):2127-36. PubMed ID: 26346170
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma.
    Stevens EV; Raffeld M; Espina V; Kristensen GB; Trope' CG; Kohn EC; Davidson B
    Cancer; 2005 Jun; 103(11):2313-9. PubMed ID: 15844177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Xeroderma pigmentosum complementation group A protein (XPA) modulates RPA-DNA interactions via enhanced complex stability and inhibition of strand separation activity.
    Patrick SM; Turchi JJ
    J Biol Chem; 2002 May; 277(18):16096-101. PubMed ID: 11859086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. XPA protein as a limiting factor for nucleotide excision repair and UV sensitivity in human cells.
    Köberle B; Roginskaya V; Wood RD
    DNA Repair (Amst); 2006 May; 5(5):641-8. PubMed ID: 16413230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NDRG1 disruption alleviates cisplatin/sodium glycididazole-induced DNA damage response and apoptosis in ERCC1-defective lung cancer cells.
    He L; Liu K; Wang X; Chen H; Zhou J; Wu X; Liu T; Yang Y; Yang X; Cui D; Song G; Wang J; Lei J
    Int J Biochem Cell Biol; 2018 Jul; 100():54-60. PubMed ID: 29768183
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Small Molecule Antagonists of the DNA Repair ERCC1/XPA Protein-Protein Interaction.
    Obermann R; Yemane B; Jarvis C; Franco FM; Kyriukha Y; Nolan W; Gohara B; Krezel AM; Wildman SA; Janetka JW
    ChemMedChem; 2024 Apr; 19(8):e202300648. PubMed ID: 38300970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DNA Repair Gene Polymorphisms in Relation to Non-Small Cell Lung Cancer Survival.
    Su Y; Zhang H; Xu F; Kong J; Yu H; Qian B
    Cell Physiol Biochem; 2015; 36(4):1419-29. PubMed ID: 26159902
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ku80 is highly expressed in lung adenocarcinoma and promotes cisplatin resistance.
    Ma Q; Li P; Xu M; Yin J; Su Z; Li W; Zhang J
    J Exp Clin Cancer Res; 2012 Nov; 31(1):99. PubMed ID: 23181744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nucleotide excision repair by mutant xeroderma pigmentosum group A (XPA) proteins with deficiency in interaction with RPA.
    Saijo M; Takedachi A; Tanaka K
    J Biol Chem; 2011 Feb; 286(7):5476-83. PubMed ID: 21148310
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypoxia promotes mitochondrial glutamine metabolism through HIF1α-GDH pathway in human lung cancer cells.
    Jiang ZF; Wang M; Xu JL; Ning YJ
    Biochem Biophys Res Commun; 2017 Jan; 483(1):32-38. PubMed ID: 28065856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The functional status of DNA repair pathways determines the sensitization effect to cisplatin in non-small cell lung cancer cells.
    Chen P; Li J; Chen YC; Qian H; Chen YJ; Su JY; Wu M; Lan T
    Cell Oncol (Dordr); 2016 Dec; 39(6):511-522. PubMed ID: 27473273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The combination therapy of HIF1α inhibitor LW6 and cisplatin plays an effective role on anti-tumor function in A549 cells.
    Mai L; Luo M; Wu JJ; Yang JH; Hong LY
    Neoplasma; 2019 Sep; 66(5):776-784. PubMed ID: 31169018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.